Maroney Dawn Christine sold $586K of ALHC

Maroney Dawn Christine (President) sold 30,000 shares of Alignment Healthcare, Inc. (ALHC) at $19.55 ($0.59M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maroney Dawn Christine
Published Jun 15, 2026, 11:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 11:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The newest disclosed fact is the officer’s open-market sale of 30,000 shares at a stated price, with holdings after the transaction and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Provides a concrete, same-day insider sale datapoint that can influence short-term sentiment, though 10b5-1 reduces interpretive weight.

03

What to watch

Traders may over-weight insider sales; the key incremental information here is the exact share count, price, and that the plan is pre-arranged.

Relevance 4/10Novelty 6/10Timing: SEC Form 4 filed on 2026-06-15 (transaction dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare President Maroney Dawn Christine sold 30,000 shares in an open-market transaction at $19.5475 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted given the 10b5-1 pre-arranged nature.

Evidence & confidence

The filing provides a concrete transaction size and price, but the presence of a pre-arranged 10b5-1 plan typically lowers interpretive value versus discretionary selling.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction disclosure (ALHC).

  • Maroney Dawn Christine

    President and reporting officer who sold 30,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.